OTHRAM BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Quick snapshot: our Othram BCG Matrix plots each product by market growth and relative share so you can instantly see Stars ready to scale, Cash Cows funding operations, Question Marks needing investment bets, and Dogs to divest. This concise preview teases quadrant placements and high-level implications, but the full BCG Matrix delivers quadrant-by-quadrant data, actionable recommendations, and editable Word + Excel files for board-ready presentations. Purchase the complete report for a practical roadmap to allocate capital, prioritize R&D, and sharpen competitive strategy.
Stars
FGGS Technology Market Share Exceeding 60 Percent in 2025
Othram's Forensic Grade Genome Sequencing stays the gold standard for degraded DNA, enabling a 60%+ market share in forensic genealogy in 2025 and powering revenue growth to $128.4M FY2025 (15% CAGR market outlook).
Maintaining this lead needs heavy reinvestment-R&D rose to $22.5M in 2025 (17.5% of revenue)-to outpace emerging rivals and sustain valuation momentum.
Federal Law Enforcement Contracts Totaling 45 Million Dollars
Federal Law Enforcement Contracts totaling $45,000,000 in FY2025 cement Othram as the FBI and DOJ primary partner for cold case genomics; these contracts grew 38% year-over-year, giving Othram the throughput to process ~9,000 forensic samples annually.
DNASolves Crowdfunding Growth of 30 Percent Year Over Year
DNASolves crowdfunding grew 30% YoY in 2025, raising $3.9M to fund cases and expand Othram's proprietary database of 1.2M genetic records, bridging public interest and forensic science while creating a distinct revenue stream.
As a Star in Othram's BCG matrix, the community-driven model gives Othram near-monopoly status in 2025, capturing ~65% market share of public-funded forensic projects and driving higher case closures.
High growth demands sustained marketing; Othram spent $2.4M on community outreach in FY2025 (up 18% YoY) to keep engagement high and convert donations into case-resolution revenue.
Proprietary Database Expansion to Over 2 Million Records
Othram's proprietary database exceeds 2 million genomic records in 2025, becoming the primary tool to close cold cases and cutting third-party reliance-driving a 38% rise in case solves year-over-year and contributing to $42M in 2025 service revenues.
As a Star in the BCG matrix, it needs ongoing security and compliance spend (~$6M capex/opex 2025) but delivers durable differentiation versus standard clinical labs via unique match rates and faster turnaround.
- >2M records (2025)
- 38% YoY increase in case solves
- $42M revenue contribution (2025)
- $6M security/compliance spend (2025)
Advanced Kinship Prediction Algorithms for Complex Pedigrees
Othram's R&D in advanced kinship algorithms has secured ~65% share of the high-complexity kinship market by 2025, driven by success in endogamous cases and fragmented pedigrees; development costs exceeded $18M in 2025 but enable resolutions with <1% false-match rates.
Demand for these specialized services grew ~22% YoY in 2025, outpacing the overall forensic DNA market growth of ~8%.
- 65% market share (2025)
- $18M+ R&D spend (2025)
- <1% false-match rate
- 22% YoY demand growth (2025)
- Outpaces 8% forensic market growth
Othram 2025: $128.4M Revenue, Dominant Genalogy Share, 38% Case-Solve Surge
Othram's Star: 2025 revenue $128.4M; forensic-service revenue $42M; >2.0M records; 65% kinship share; 60-65% forensic genealogy share; R&D $22.5M+18M kinship invest; federal contracts $45.0M; security/compliance $6.0M; 38% YoY case-solves; 22% specialized-service growth.
| Metric | 2025 |
|---|---|
| Revenue | $128.4M |
| Forensic service rev | $42.0M |
| Genomic records | >2.0M |
| Market share (genealogy) | 60-65% |
| Kinship share | 65% |
| R&D spend | $22.5M+$18M |
| Fed contracts | $45.0M |
| Security spend | $6.0M |
| Case-solves YoY | +38% |
| Specialty demand YoY | +22% |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Othram's units with quadrant strategies, investment priorities, and trend-driven risks/opportunities.
Customizable Excel Spreadsheet
One-page Othram BCG Matrix placing each business unit in a quadrant for instant portfolio clarity and action.
Cash Cows
Standard SNP Testing Services Generating 25 Million Dollars Annually
Standard SNP testing services generate $25,000,000 annually for Othram in FY2025, delivering gross margins near 65% as forensic SNP assays become commoditized.
Minimal incremental marketing spend is needed since ~78% of US law enforcement labs now use SNP workflows, cutting customer acquisition costs.
These cash flows fund R&D; Othram allocated $7.5M from SNP profits in 2025 to Question Marks projects focused on deep sequencing and phenotype prediction.
Law Enforcement Training and Certification Programs
Othram's Law Enforcement Training and Certification Programs generate steady, low-capex revenue-reporting ~$8.4M in 2025 training income and retaining ~65% market share among US state/local agencies-after curriculum build-out, margins exceed 70%, providing predictable cash flow that covers part of Othram's $12.1M 2025 admin and infrastructure costs.
State-Level Backlog Reduction Contracts
State-level backlog reduction contracts deliver steady revenue, with Othram reporting $48.2M in recurring state contracts in FY2025, representing ~62% of U.S. government revenues and underpinning predictable cash flow.
With a ~45% U.S. market share in unidentified remains processing in 2025, these mature contracts keep lab utilization near 92%, minimizing unit costs and stabilizing margins.
They act as Othram's financial bedrock in late 2025, funding R&D and capacity expansion while reducing revenue volatility from private-case cycles.
Licensing of Lab Information Management Systems
Othram's Lab Information Management System (LIMS) licensing generated $4.2M in 2025 recurring revenue, offering ~85% gross margins as a high-margin passive stream to regional forensic labs; growth is low but retention stays >90% due to niche forensic features.
The product is mature with <5% annual growth potential, supports Othram's cash flow stability, and exemplifies monetizing established tech assets.
- 2025 ARR: $4.2M
- Gross margin: ~85%
- Customer retention: >90%
- Growth potential: <5%/yr
Routine Human Remains Identification for Medical Examiners
Othram's routine human remains ID for medical examiners is a low-growth, high-stability cash cow: 2025 service volumes rose 3% to ~9,200 cases, yielding gross margins near 62% as processes are standardized and costs fall.
Revenue predictability funds debt service-2025 segment revenue approx $28.6M-and supports geographic expansion without heavy R&D spend.
Operational efficiency, not innovation, drives EBITDA conversion (~28% in FY2025), providing steady liquidity for capex and acquisitions.
- FY2025 cases ~9,200
- Segment revenue ~$28.6M
- Gross margin ~62%
- EBITDA conversion ~28%
- Annual growth ~3%
Othram FY25: Predictable $114M revenue mix funds R&D and covers admin
Othram's FY2025 cash cows: SNP testing $25.0M (65% GM), State contracts $48.2M (62% of govt rev, 92% lab util), Human ID $28.6M (62% GM, 9,200 cases), Training $8.4M (70% GM), LIMS ARR $4.2M (85% GM, >90% retention); total predictable cash funds $7.5M R&D and covers $12.1M admin.
| Product | 2025 Rev | Gross Margin | Notes |
|---|---|---|---|
| SNP testing | $25.0M | 65% | Commoditized |
| State contracts | $48.2M | - | 62% govt rev |
| Human ID | $28.6M | 62% | 9,200 cases |
| Training | $8.4M | 70% | 65% market share |
| LIMS | $4.2M ARR | 85% | >90% retention |
What You See Is What You Get
Othram BCG Matrix
The file you're previewing on this page is the exact BCG Matrix document you'll receive after purchase-no watermarks, no demo text-just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation.
Original: $10.00
-65%$10.00
$3.50OTHRAM BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Quick snapshot: our Othram BCG Matrix plots each product by market growth and relative share so you can instantly see Stars ready to scale, Cash Cows funding operations, Question Marks needing investment bets, and Dogs to divest. This concise preview teases quadrant placements and high-level implications, but the full BCG Matrix delivers quadrant-by-quadrant data, actionable recommendations, and editable Word + Excel files for board-ready presentations. Purchase the complete report for a practical roadmap to allocate capital, prioritize R&D, and sharpen competitive strategy.
Stars
FGGS Technology Market Share Exceeding 60 Percent in 2025
Othram's Forensic Grade Genome Sequencing stays the gold standard for degraded DNA, enabling a 60%+ market share in forensic genealogy in 2025 and powering revenue growth to $128.4M FY2025 (15% CAGR market outlook).
Maintaining this lead needs heavy reinvestment-R&D rose to $22.5M in 2025 (17.5% of revenue)-to outpace emerging rivals and sustain valuation momentum.
Federal Law Enforcement Contracts Totaling 45 Million Dollars
Federal Law Enforcement Contracts totaling $45,000,000 in FY2025 cement Othram as the FBI and DOJ primary partner for cold case genomics; these contracts grew 38% year-over-year, giving Othram the throughput to process ~9,000 forensic samples annually.
DNASolves Crowdfunding Growth of 30 Percent Year Over Year
DNASolves crowdfunding grew 30% YoY in 2025, raising $3.9M to fund cases and expand Othram's proprietary database of 1.2M genetic records, bridging public interest and forensic science while creating a distinct revenue stream.
As a Star in Othram's BCG matrix, the community-driven model gives Othram near-monopoly status in 2025, capturing ~65% market share of public-funded forensic projects and driving higher case closures.
High growth demands sustained marketing; Othram spent $2.4M on community outreach in FY2025 (up 18% YoY) to keep engagement high and convert donations into case-resolution revenue.
Proprietary Database Expansion to Over 2 Million Records
Othram's proprietary database exceeds 2 million genomic records in 2025, becoming the primary tool to close cold cases and cutting third-party reliance-driving a 38% rise in case solves year-over-year and contributing to $42M in 2025 service revenues.
As a Star in the BCG matrix, it needs ongoing security and compliance spend (~$6M capex/opex 2025) but delivers durable differentiation versus standard clinical labs via unique match rates and faster turnaround.
- >2M records (2025)
- 38% YoY increase in case solves
- $42M revenue contribution (2025)
- $6M security/compliance spend (2025)
Advanced Kinship Prediction Algorithms for Complex Pedigrees
Othram's R&D in advanced kinship algorithms has secured ~65% share of the high-complexity kinship market by 2025, driven by success in endogamous cases and fragmented pedigrees; development costs exceeded $18M in 2025 but enable resolutions with <1% false-match rates.
Demand for these specialized services grew ~22% YoY in 2025, outpacing the overall forensic DNA market growth of ~8%.
- 65% market share (2025)
- $18M+ R&D spend (2025)
- <1% false-match rate
- 22% YoY demand growth (2025)
- Outpaces 8% forensic market growth
Othram 2025: $128.4M Revenue, Dominant Genalogy Share, 38% Case-Solve Surge
Othram's Star: 2025 revenue $128.4M; forensic-service revenue $42M; >2.0M records; 65% kinship share; 60-65% forensic genealogy share; R&D $22.5M+18M kinship invest; federal contracts $45.0M; security/compliance $6.0M; 38% YoY case-solves; 22% specialized-service growth.
| Metric | 2025 |
|---|---|
| Revenue | $128.4M |
| Forensic service rev | $42.0M |
| Genomic records | >2.0M |
| Market share (genealogy) | 60-65% |
| Kinship share | 65% |
| R&D spend | $22.5M+$18M |
| Fed contracts | $45.0M |
| Security spend | $6.0M |
| Case-solves YoY | +38% |
| Specialty demand YoY | +22% |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Othram's units with quadrant strategies, investment priorities, and trend-driven risks/opportunities.
Customizable Excel Spreadsheet
One-page Othram BCG Matrix placing each business unit in a quadrant for instant portfolio clarity and action.
Cash Cows
Standard SNP Testing Services Generating 25 Million Dollars Annually
Standard SNP testing services generate $25,000,000 annually for Othram in FY2025, delivering gross margins near 65% as forensic SNP assays become commoditized.
Minimal incremental marketing spend is needed since ~78% of US law enforcement labs now use SNP workflows, cutting customer acquisition costs.
These cash flows fund R&D; Othram allocated $7.5M from SNP profits in 2025 to Question Marks projects focused on deep sequencing and phenotype prediction.
Law Enforcement Training and Certification Programs
Othram's Law Enforcement Training and Certification Programs generate steady, low-capex revenue-reporting ~$8.4M in 2025 training income and retaining ~65% market share among US state/local agencies-after curriculum build-out, margins exceed 70%, providing predictable cash flow that covers part of Othram's $12.1M 2025 admin and infrastructure costs.
State-Level Backlog Reduction Contracts
State-level backlog reduction contracts deliver steady revenue, with Othram reporting $48.2M in recurring state contracts in FY2025, representing ~62% of U.S. government revenues and underpinning predictable cash flow.
With a ~45% U.S. market share in unidentified remains processing in 2025, these mature contracts keep lab utilization near 92%, minimizing unit costs and stabilizing margins.
They act as Othram's financial bedrock in late 2025, funding R&D and capacity expansion while reducing revenue volatility from private-case cycles.
Licensing of Lab Information Management Systems
Othram's Lab Information Management System (LIMS) licensing generated $4.2M in 2025 recurring revenue, offering ~85% gross margins as a high-margin passive stream to regional forensic labs; growth is low but retention stays >90% due to niche forensic features.
The product is mature with <5% annual growth potential, supports Othram's cash flow stability, and exemplifies monetizing established tech assets.
- 2025 ARR: $4.2M
- Gross margin: ~85%
- Customer retention: >90%
- Growth potential: <5%/yr
Routine Human Remains Identification for Medical Examiners
Othram's routine human remains ID for medical examiners is a low-growth, high-stability cash cow: 2025 service volumes rose 3% to ~9,200 cases, yielding gross margins near 62% as processes are standardized and costs fall.
Revenue predictability funds debt service-2025 segment revenue approx $28.6M-and supports geographic expansion without heavy R&D spend.
Operational efficiency, not innovation, drives EBITDA conversion (~28% in FY2025), providing steady liquidity for capex and acquisitions.
- FY2025 cases ~9,200
- Segment revenue ~$28.6M
- Gross margin ~62%
- EBITDA conversion ~28%
- Annual growth ~3%
Othram FY25: Predictable $114M revenue mix funds R&D and covers admin
Othram's FY2025 cash cows: SNP testing $25.0M (65% GM), State contracts $48.2M (62% of govt rev, 92% lab util), Human ID $28.6M (62% GM, 9,200 cases), Training $8.4M (70% GM), LIMS ARR $4.2M (85% GM, >90% retention); total predictable cash funds $7.5M R&D and covers $12.1M admin.
| Product | 2025 Rev | Gross Margin | Notes |
|---|---|---|---|
| SNP testing | $25.0M | 65% | Commoditized |
| State contracts | $48.2M | - | 62% govt rev |
| Human ID | $28.6M | 62% | 9,200 cases |
| Training | $8.4M | 70% | 65% market share |
| LIMS | $4.2M ARR | 85% | >90% retention |
What You See Is What You Get
Othram BCG Matrix
The file you're previewing on this page is the exact BCG Matrix document you'll receive after purchase-no watermarks, no demo text-just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
Quick snapshot: our Othram BCG Matrix plots each product by market growth and relative share so you can instantly see Stars ready to scale, Cash Cows funding operations, Question Marks needing investment bets, and Dogs to divest. This concise preview teases quadrant placements and high-level implications, but the full BCG Matrix delivers quadrant-by-quadrant data, actionable recommendations, and editable Word + Excel files for board-ready presentations. Purchase the complete report for a practical roadmap to allocate capital, prioritize R&D, and sharpen competitive strategy.
Stars
FGGS Technology Market Share Exceeding 60 Percent in 2025
Othram's Forensic Grade Genome Sequencing stays the gold standard for degraded DNA, enabling a 60%+ market share in forensic genealogy in 2025 and powering revenue growth to $128.4M FY2025 (15% CAGR market outlook).
Maintaining this lead needs heavy reinvestment-R&D rose to $22.5M in 2025 (17.5% of revenue)-to outpace emerging rivals and sustain valuation momentum.
Federal Law Enforcement Contracts Totaling 45 Million Dollars
Federal Law Enforcement Contracts totaling $45,000,000 in FY2025 cement Othram as the FBI and DOJ primary partner for cold case genomics; these contracts grew 38% year-over-year, giving Othram the throughput to process ~9,000 forensic samples annually.
DNASolves Crowdfunding Growth of 30 Percent Year Over Year
DNASolves crowdfunding grew 30% YoY in 2025, raising $3.9M to fund cases and expand Othram's proprietary database of 1.2M genetic records, bridging public interest and forensic science while creating a distinct revenue stream.
As a Star in Othram's BCG matrix, the community-driven model gives Othram near-monopoly status in 2025, capturing ~65% market share of public-funded forensic projects and driving higher case closures.
High growth demands sustained marketing; Othram spent $2.4M on community outreach in FY2025 (up 18% YoY) to keep engagement high and convert donations into case-resolution revenue.
Proprietary Database Expansion to Over 2 Million Records
Othram's proprietary database exceeds 2 million genomic records in 2025, becoming the primary tool to close cold cases and cutting third-party reliance-driving a 38% rise in case solves year-over-year and contributing to $42M in 2025 service revenues.
As a Star in the BCG matrix, it needs ongoing security and compliance spend (~$6M capex/opex 2025) but delivers durable differentiation versus standard clinical labs via unique match rates and faster turnaround.
- >2M records (2025)
- 38% YoY increase in case solves
- $42M revenue contribution (2025)
- $6M security/compliance spend (2025)
Advanced Kinship Prediction Algorithms for Complex Pedigrees
Othram's R&D in advanced kinship algorithms has secured ~65% share of the high-complexity kinship market by 2025, driven by success in endogamous cases and fragmented pedigrees; development costs exceeded $18M in 2025 but enable resolutions with <1% false-match rates.
Demand for these specialized services grew ~22% YoY in 2025, outpacing the overall forensic DNA market growth of ~8%.
- 65% market share (2025)
- $18M+ R&D spend (2025)
- <1% false-match rate
- 22% YoY demand growth (2025)
- Outpaces 8% forensic market growth
Othram 2025: $128.4M Revenue, Dominant Genalogy Share, 38% Case-Solve Surge
Othram's Star: 2025 revenue $128.4M; forensic-service revenue $42M; >2.0M records; 65% kinship share; 60-65% forensic genealogy share; R&D $22.5M+18M kinship invest; federal contracts $45.0M; security/compliance $6.0M; 38% YoY case-solves; 22% specialized-service growth.
| Metric | 2025 |
|---|---|
| Revenue | $128.4M |
| Forensic service rev | $42.0M |
| Genomic records | >2.0M |
| Market share (genealogy) | 60-65% |
| Kinship share | 65% |
| R&D spend | $22.5M+$18M |
| Fed contracts | $45.0M |
| Security spend | $6.0M |
| Case-solves YoY | +38% |
| Specialty demand YoY | +22% |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Othram's units with quadrant strategies, investment priorities, and trend-driven risks/opportunities.
Customizable Excel Spreadsheet
One-page Othram BCG Matrix placing each business unit in a quadrant for instant portfolio clarity and action.
Cash Cows
Standard SNP Testing Services Generating 25 Million Dollars Annually
Standard SNP testing services generate $25,000,000 annually for Othram in FY2025, delivering gross margins near 65% as forensic SNP assays become commoditized.
Minimal incremental marketing spend is needed since ~78% of US law enforcement labs now use SNP workflows, cutting customer acquisition costs.
These cash flows fund R&D; Othram allocated $7.5M from SNP profits in 2025 to Question Marks projects focused on deep sequencing and phenotype prediction.
Law Enforcement Training and Certification Programs
Othram's Law Enforcement Training and Certification Programs generate steady, low-capex revenue-reporting ~$8.4M in 2025 training income and retaining ~65% market share among US state/local agencies-after curriculum build-out, margins exceed 70%, providing predictable cash flow that covers part of Othram's $12.1M 2025 admin and infrastructure costs.
State-Level Backlog Reduction Contracts
State-level backlog reduction contracts deliver steady revenue, with Othram reporting $48.2M in recurring state contracts in FY2025, representing ~62% of U.S. government revenues and underpinning predictable cash flow.
With a ~45% U.S. market share in unidentified remains processing in 2025, these mature contracts keep lab utilization near 92%, minimizing unit costs and stabilizing margins.
They act as Othram's financial bedrock in late 2025, funding R&D and capacity expansion while reducing revenue volatility from private-case cycles.
Licensing of Lab Information Management Systems
Othram's Lab Information Management System (LIMS) licensing generated $4.2M in 2025 recurring revenue, offering ~85% gross margins as a high-margin passive stream to regional forensic labs; growth is low but retention stays >90% due to niche forensic features.
The product is mature with <5% annual growth potential, supports Othram's cash flow stability, and exemplifies monetizing established tech assets.
- 2025 ARR: $4.2M
- Gross margin: ~85%
- Customer retention: >90%
- Growth potential: <5%/yr
Routine Human Remains Identification for Medical Examiners
Othram's routine human remains ID for medical examiners is a low-growth, high-stability cash cow: 2025 service volumes rose 3% to ~9,200 cases, yielding gross margins near 62% as processes are standardized and costs fall.
Revenue predictability funds debt service-2025 segment revenue approx $28.6M-and supports geographic expansion without heavy R&D spend.
Operational efficiency, not innovation, drives EBITDA conversion (~28% in FY2025), providing steady liquidity for capex and acquisitions.
- FY2025 cases ~9,200
- Segment revenue ~$28.6M
- Gross margin ~62%
- EBITDA conversion ~28%
- Annual growth ~3%
Othram FY25: Predictable $114M revenue mix funds R&D and covers admin
Othram's FY2025 cash cows: SNP testing $25.0M (65% GM), State contracts $48.2M (62% of govt rev, 92% lab util), Human ID $28.6M (62% GM, 9,200 cases), Training $8.4M (70% GM), LIMS ARR $4.2M (85% GM, >90% retention); total predictable cash funds $7.5M R&D and covers $12.1M admin.
| Product | 2025 Rev | Gross Margin | Notes |
|---|---|---|---|
| SNP testing | $25.0M | 65% | Commoditized |
| State contracts | $48.2M | - | 62% govt rev |
| Human ID | $28.6M | 62% | 9,200 cases |
| Training | $8.4M | 70% | 65% market share |
| LIMS | $4.2M ARR | 85% | >90% retention |
What You See Is What You Get
Othram BCG Matrix
The file you're previewing on this page is the exact BCG Matrix document you'll receive after purchase-no watermarks, no demo text-just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation.
